Crbn Ddb1 | Ddb1 cosmic, sanger institute somatic mutation information and related details. Crl4(crbn) e3 ubiquitin ligase inhibitor. Pdb rendering based on 2b5l. Reproducible results in bioactivity assays. Interaction types & directionality mechanism of interaction.
Such complexes are also known as e3 ubiquitin ligases. Crl4(crbn) e3 ubiquitin ligase inhibitor. They are suitable for use in applications related to the study of b cell malignancies (multiple myeloma. Pdb rendering based on 2b5l. Ddb1 (damage specific dna binding protein 1) is a interacts with ambra1, atg16l1, btrc, crbn, dcaf1, dcaf4, dcaf5, dcaf6, dcaf7, dcaf8, dcaf9.
Reproducible results in bioactivity assays. (b) crbn overexpression promotes assembly of active crl4crbn complexes, likely by outcompeting other ddb1/dcaf substrate recognition modules for limiting pools of cul4a/b. Interaction types & directionality mechanism of interaction. Crl4(crbn) e3 ubiquitin ligase inhibitor. Thalidomide targets to crbn with ic50 of 8.5 nm. Ddb1 (damage specific dna binding protein 1) is a interacts with ambra1, atg16l1, btrc, crbn, dcaf1, dcaf4, dcaf5, dcaf6, dcaf7, dcaf8, dcaf9. Pdb rendering based on 2b5l. Such complexes are also known as e3 ubiquitin ligases.
Ddb1 (damage specific dna binding protein 1) is a interacts with ambra1, atg16l1, btrc, crbn, dcaf1, dcaf4, dcaf5, dcaf6, dcaf7, dcaf8, dcaf9. Ddb1 geo profiles, ncbi search the gene expression profiles from curated datasets in the gene expression omnibus. Ddb1 cosmic, sanger institute somatic mutation information and related details. Thalidomide targets to crbn with ic50 of 8.5 nm. Reproducible results in bioactivity assays. Pdb rendering based on 2b5l. (b) crbn overexpression promotes assembly of active crl4crbn complexes, likely by outcompeting other ddb1/dcaf substrate recognition modules for limiting pools of cul4a/b. Such complexes are also known as e3 ubiquitin ligases. They are suitable for use in applications related to the study of b cell malignancies (multiple myeloma. Crl4(crbn) e3 ubiquitin ligase inhibitor. Implication for aldosteronism and leukodystrophy. Interaction types & directionality mechanism of interaction. Genecards summary for ddb1 gene.
Such complexes are also known as e3 ubiquitin ligases. (b) crbn overexpression promotes assembly of active crl4crbn complexes, likely by outcompeting other ddb1/dcaf substrate recognition modules for limiting pools of cul4a/b. Thalidomide targets to crbn with ic50 of 8.5 nm. Reproducible results in bioactivity assays. Crl4(crbn) e3 ubiquitin ligase inhibitor.
Crl4(crbn) e3 ubiquitin ligase inhibitor. Interaction types & directionality mechanism of interaction. Genecards summary for ddb1 gene. Thalidomide targets to crbn with ic50 of 8.5 nm. Ddb1 (damage specific dna binding protein 1) is a interacts with ambra1, atg16l1, btrc, crbn, dcaf1, dcaf4, dcaf5, dcaf6, dcaf7, dcaf8, dcaf9. Pdb rendering based on 2b5l. (b) crbn overexpression promotes assembly of active crl4crbn complexes, likely by outcompeting other ddb1/dcaf substrate recognition modules for limiting pools of cul4a/b. They are suitable for use in applications related to the study of b cell malignancies (multiple myeloma.
Interaction types & directionality mechanism of interaction. Thalidomide targets to crbn with ic50 of 8.5 nm. Pdb rendering based on 2b5l. Genecards summary for ddb1 gene. (b) crbn overexpression promotes assembly of active crl4crbn complexes, likely by outcompeting other ddb1/dcaf substrate recognition modules for limiting pools of cul4a/b. Reproducible results in bioactivity assays. Ddb1 cosmic, sanger institute somatic mutation information and related details. Such complexes are also known as e3 ubiquitin ligases. They are suitable for use in applications related to the study of b cell malignancies (multiple myeloma. Ddb1 (damage specific dna binding protein 1) is a interacts with ambra1, atg16l1, btrc, crbn, dcaf1, dcaf4, dcaf5, dcaf6, dcaf7, dcaf8, dcaf9. Ddb1 geo profiles, ncbi search the gene expression profiles from curated datasets in the gene expression omnibus. Implication for aldosteronism and leukodystrophy. Crl4(crbn) e3 ubiquitin ligase inhibitor.
Implication for aldosteronism and leukodystrophy. Genecards summary for ddb1 gene. Crl4(crbn) e3 ubiquitin ligase inhibitor. Interaction types & directionality mechanism of interaction. Ddb1 (damage specific dna binding protein 1) is a interacts with ambra1, atg16l1, btrc, crbn, dcaf1, dcaf4, dcaf5, dcaf6, dcaf7, dcaf8, dcaf9.
Ddb1 geo profiles, ncbi search the gene expression profiles from curated datasets in the gene expression omnibus. Crl4(crbn) e3 ubiquitin ligase inhibitor. Thalidomide targets to crbn with ic50 of 8.5 nm. Interaction types & directionality mechanism of interaction. They are suitable for use in applications related to the study of b cell malignancies (multiple myeloma. Such complexes are also known as e3 ubiquitin ligases. Reproducible results in bioactivity assays. Genecards summary for ddb1 gene.
They are suitable for use in applications related to the study of b cell malignancies (multiple myeloma. Reproducible results in bioactivity assays. Genecards summary for ddb1 gene. Ddb1 cosmic, sanger institute somatic mutation information and related details. Implication for aldosteronism and leukodystrophy. Thalidomide targets to crbn with ic50 of 8.5 nm. Interaction types & directionality mechanism of interaction. Crl4(crbn) e3 ubiquitin ligase inhibitor. Such complexes are also known as e3 ubiquitin ligases. Pdb rendering based on 2b5l. Ddb1 geo profiles, ncbi search the gene expression profiles from curated datasets in the gene expression omnibus. (b) crbn overexpression promotes assembly of active crl4crbn complexes, likely by outcompeting other ddb1/dcaf substrate recognition modules for limiting pools of cul4a/b. Ddb1 (damage specific dna binding protein 1) is a interacts with ambra1, atg16l1, btrc, crbn, dcaf1, dcaf4, dcaf5, dcaf6, dcaf7, dcaf8, dcaf9.
Crl4(crbn) e3 ubiquitin ligase inhibitor crbn. Interaction types & directionality mechanism of interaction.
Crbn Ddb1! Genecards summary for ddb1 gene.
No comments:
Post a Comment